Interface Laboratories

Company Overview

Interface Laboratories is a biotechnology startup founded in 2021 by a pediatric infectious disease specialist with deep expertise in microbiome research and bioinformatics. We are dedicated to addressing critical gaps in infectious disease management through innovative diagnostics, targeted therapeutics, and advanced computational tools.

Our Mission

We bridge clinical insights with cutting-edge technology to develop practical solutions that improve patient outcomes while advancing the science of infectious disease treatment and monitoring. Our work spans from bench to bedside, leveraging our unique position at the interface of clinical practice, research, and computational biology to tackle challenges that traditional approaches have struggled to address.

Our Values

• Scientific Innovation: Translating clinical needs into technological solutions through rigorous research and development.
• Data-Driven Approach: Leveraging bioinformatics and machine learning for better diagnostic and therapeutic outcomes.
• Clinical Relevance: Ensuring our solutions address real-world healthcare challenges faced by patients and providers.
• Collaborative Development: Working closely with clinicians, researchers, and healthcare systems to validate and implement our innovations.

Our Approach

At Interface Laboratories, we believe that the most impactful solutions emerge at the intersection of different disciplines. Our integrated approach combines:

• Clinical Expertise: Direct patient care experience informing our development priorities
• Advanced Computational Methods: Bioinformatics and machine learning for data-driven insights
• Structural Biology Insights: Rational drug design based on molecular understanding
• Microbiome Research: Understanding complex host-pathogen interactions

This multidisciplinary foundation enables us to develop solutions that are both scientifically innovative and clinically practical.

Key Achievements

• Innovative Diagnostics: Development of C. difficile diagnostic assays with promising preliminary data
• Drug Discovery: Novel antifungal and antiparasitic compounds in preclinical development
• BioGPU Platform: Beta launch for rapid metagenomic profiling and analysis
• Therapeutic Monitoring: Active services for antimicrobial optimization in clinical settings
• Strategic Partnerships: Collaborations with healthcare systems and research institutions